Tags

Type your tag names separated by a space and hit enter

Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
MMWR Morb Mortal Wkly Rep. 2011 May 27; 60(20):661-3.MM

Abstract

Japanese encephalitis (JE) virus, a mosquito-borne flavivirus, is an important cause of encephalitis in Asia with a case fatality rate of 20%--30% and neurologic or psychiatric sequelae in 30%--50% of survivors (1). Travelers to JE-endemic countries and laboratory personnel who work with infectious JE virus are at potential risk for JE virus infection. In 2010, CDC's Advisory Committee on Immunization Practices (ACIP) updated recommendations for prevention of JE. The updated recommendations included information on use of a new inactivated, Vero cell culture--derived JE vaccine (JE-VC [manufactured as Ixiaro]) that was licensed in the United States in 2009. Data on the need for and timing of booster doses with JE-VC were not available when the vaccine was licensed. This report summarizes new data on the persistence of neutralizing antibodies following primary vaccination with JE-VC and the safety and immunogenicity of a booster dose of JE-VC. The report also provides updated guidance to health-care personnel regarding use of a booster dose of JE-VC for U.S. travelers and laboratory personnel. ACIP recommends that if the primary series of JE-VC was administered >1 year previously, a booster dose may be given before potential JE virus exposure.

Authors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21617632

Citation

Centers for Disease Control and Prevention (CDC). "Recommendations for Use of a Booster Dose of Inactivated Vero Cell Culture-derived Japanese Encephalitis Vaccine: Advisory Committee On Immunization Practices, 2011." MMWR. Morbidity and Mortality Weekly Report, vol. 60, no. 20, 2011, pp. 661-3.
Centers for Disease Control and Prevention (CDC). Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(20):661-3.
Centers for Disease Control and Prevention (CDC). (2011). Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR. Morbidity and Mortality Weekly Report, 60(20), 661-3.
Centers for Disease Control and Prevention (CDC). Recommendations for Use of a Booster Dose of Inactivated Vero Cell Culture-derived Japanese Encephalitis Vaccine: Advisory Committee On Immunization Practices, 2011. MMWR Morb Mortal Wkly Rep. 2011 May 27;60(20):661-3. PubMed PMID: 21617632.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. A1 - ,, PY - 2011/5/28/entrez PY - 2011/5/28/pubmed PY - 2011/7/19/medline SP - 661 EP - 3 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb. Mortal. Wkly. Rep. VL - 60 IS - 20 N2 - Japanese encephalitis (JE) virus, a mosquito-borne flavivirus, is an important cause of encephalitis in Asia with a case fatality rate of 20%--30% and neurologic or psychiatric sequelae in 30%--50% of survivors (1). Travelers to JE-endemic countries and laboratory personnel who work with infectious JE virus are at potential risk for JE virus infection. In 2010, CDC's Advisory Committee on Immunization Practices (ACIP) updated recommendations for prevention of JE. The updated recommendations included information on use of a new inactivated, Vero cell culture--derived JE vaccine (JE-VC [manufactured as Ixiaro]) that was licensed in the United States in 2009. Data on the need for and timing of booster doses with JE-VC were not available when the vaccine was licensed. This report summarizes new data on the persistence of neutralizing antibodies following primary vaccination with JE-VC and the safety and immunogenicity of a booster dose of JE-VC. The report also provides updated guidance to health-care personnel regarding use of a booster dose of JE-VC for U.S. travelers and laboratory personnel. ACIP recommends that if the primary series of JE-VC was administered >1 year previously, a booster dose may be given before potential JE virus exposure. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/21617632/Recommendations_for_use_of_a_booster_dose_of_inactivated_vero_cell_culture_derived_Japanese_encephalitis_vaccine:_advisory_committee_on_immunization_practices_2011_ L2 - https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6020a5.htm DB - PRIME DP - Unbound Medicine ER -